April 3, 2018 / 6:47 AM / 19 days ago

BRIEF-Astrazeneca Says European Medicines Agency Accepts Regulatory Submission For Lynparza In Brca-Mutated, Her2 Negative Metastatic

April 3 (Reuters) - AstraZeneca PLC:

* EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA IN BRCA-MUTATED, HER2-NEGATIVE METASTATIC

* CO AND MERCK ANNOUNCES EUROPEAN MEDICINES AGENCY HAS VALIDATED FOR REVIEW MARKETING AUTHORISATION APPLICATION FOR LYNPARZA (OLAPARIB) Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below